Extensive clinical experience: Changing patterns in diagnosis and therapy of acromegaly over two decades

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 6, 2008, Pages 2035-2041

  Nachtigall, Lisa ^a   Delgado, Adriano ^a   Swearingen, Brooke ^a   Lee, Hang ^a   Zerikly, Rahfa ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; GROWTH HORMONE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; SOMATOMEDIN C;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEADACHE; HORMONE BLOOD LEVEL; HORMONE INHIBITION; HUMAN; HYPERTENSION; HYPOPITUITARISM; ISCHEMIC HEART DISEASE; LIQUORRHEA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEOPLASM; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCHOOL CHILD; SLEEP APNEA SYNDROME; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; X RAY; CASE CONTROL STUDY; CHILD; FAMILY SIZE; GENERAL PRACTITIONER; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; SECRETION; TIME;

ACROMEGALY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; COMBINED MODALITY THERAPY; FAMILY CHARACTERISTICS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PHYSICIANS, FAMILY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 45149091776     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2149     Document Type: Article

References (48)

1. Alexander L, Appleton D, Hall R, Ross WM 1980 Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12:71-79
2. Bengtsson BA, Eden S, Ernest I, Oden A 1988 Epidemiology and long term survival in acromegaly. Acta Med Scand 223:327-235
3. Ritchie CM, Atkinson AB, Kennedy AL, Lyons AR, Gordon DS, Fannin T, Hadden DR 1990 Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J 59:55-62
4. Extabe J, Gaztambide S, Latorre P, Vazquez JA 1993 Acromegaly: an epidemiological study. J Endocrinol Invest 16:181-187
5. Holdaway IM, Rajasoorya C 1999 Epidemiology of acromegaly. Pituitary 2:29-41
6. Daly AF, Petrossians P, Beckers A 2005 An overview of the epidemiology and genetics of acromegaly. J Endocrinol Invest 28(Suppl):67-69
7. Nabarro JD 1987 Acromegaly. Clin Endocrinol (Oxf) 26:481-512
8. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102
9. Bates AS, Van't Hoff W, Jones JM, Clayton RN 1993 An audit of outcome in acromegaly. Q J Med 86:293-299
10. Colao A. Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G 2001 Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557
11. Sheppard MC 2005 The critical parameters in GH excess. J Endocrinol Invest 28(Suppl):92-95
12. Arita K, Kurisu K, Tominaga A, Eguchi K 2003 Mortality in 154 surgically treated patients with acromegaly - a 10-year follow-up survey. Endocr J 50: 163-172
13. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman U, Viikari J, Voutilainen E 2005 A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081-4086
14. Swearingen B, Barker FG, Katznelson L Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
15. Puder JJ, Nilavar S, Post KD, Freda PU 2005 Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90:197-208
16. Beauregard C, Troung U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (oxf) 58:86-91
17. Ezzat S, Melmed S 1991 Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 72:245-249
18. Molitch M 1992 Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 21:597-614
19. Barker FG, Klibanski A, Swearingen B 2003 Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88:4709-4719
20. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM 1998 The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 49:653-657
21. Osman IA 1994 Factors determining the long-term outcome of surgery for acromegaly. QJM 87:617-623
22. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA 1999 Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 50:561-567
23. Long H, Beauregard H, Somma M, Comtois R, Serri O, Hardy J 1996 Surgical outcome after repeated transsphenoidal surgery in acromegaly. J Neurosurg 85:239-247
24. Ciric I, Ragin A, Baumgartner C, Pierce D 1997 Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40:225-236
25. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO 2003 Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 88:4759-4767
26. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M 2004 Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry. Eur J Endocrinol 151:439 -446
27. Melmed S, Jackson I, Kleinberg D, Klibanski A 1998 Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83:2646-2652
28. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F 1996 Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 45:407-413
29. Freda PU, Wardlaw SL, Post KD 1998 Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89:353-358
30. Klibanski A, Ho K, Freda PU, Clemmons DR, Barkan A, Kleinberg DL, Trainer PJ, Swearingen B, Molitch, ME, Wass, JA, Thorner MO, Melmed S, Strasburger CJ, Frohman, LA 2001 State-of-the art strategies for the diagnosis and management of acromegaly. Endocrinologist 11:223-232
31. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000 85:526-529
32. Klijn JGM, Lamberts SW, de Jong FH, van Dongen KJ, Birkenhager JC 1980 Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol (Copenh) 95:289-297
33. Lieberman SA, Bjorkengren AG, Hoffman AR 1992 Rheumatologic and skeletal changes in acromegaly. Endocrinol Metab Clin North Am 21:615-631
34. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102-152
35. Jadresic A, Banks LM, Child DF, Diamant L, Doyle FH, Diamant L, Fraser TR, Joplin GF 1982 The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med 202:189-204
36. Ezzat S, Forrester MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG 1994 Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 73:233-240
37. Kreutzer J, Vance ML, Lopes MB, Laws Jr ER 2001 Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072-4077
38. Nomikos P, Buchfelder M, Fahlbusch R 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure.' Eur J Endocrinol 152:379-387
39. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF 2003 Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88:3567-3572
40. Laws Jr ER, Thapar K 1999 Pituitary surgery. Endocrinol Metab Clin North Am 28:119-131
41. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM 1999 Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. QJM 92:741-745
42. Barkan AL, Halasz, I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM 1997 Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:3187-3191
43. Barrande G, Pittino-Lungo M, Coste, Ponvert D, Bertagna X, Luton JP, Bertherat J 2000 Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779-3785
44. al-Mefty O, Kersch JE, Routh A, Smith RR 1990 The long-term side effects of radiation therapy for benign brain tumors in adults. J Neurosurg 73:502-512
45. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378
46. Newman CB, Melmed S, Snyder PJ Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF 1995 Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab [Erratum (1995) 80:3238] 80:2768-2775
47. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, Jervell J 1995 Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 80:3601-3607
48. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. N Eng J Med 342:1171-1177